Opus Genetics (IRD) Cash from Investing Activities Growth (3y) (2013 - 2024)
Powered by 
Analysis
Opus Genetics (IRD) Cash from Investing Activities Growth (3y) (2013 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -44.69% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -39.73% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -246.81% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -53.57% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.84% |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 141.59% |
| Dec 31, 2021 | -27.03% |
| Dec 31, 2020 | 29.58% |
| Dec 31, 2019 | -26.54% |
| Sep 30, 2019 | 52.89% |
| Jun 30, 2019 | 6.52% |
| Mar 31, 2019 | -97.40% |
| Dec 31, 2018 | 35.13% |
| Sep 30, 2018 | -19.25% |
| Jun 30, 2018 | 7.22% |
| Mar 31, 2018 | -10.89% |
| Dec 31, 2017 | -11.10% |
| Sep 30, 2017 | 28.99% |
| Jun 30, 2017 | -413.85% |
| Mar 31, 2017 | 190.99% |
| Dec 31, 2016 | 147.31% |
| Sep 30, 2016 | -407.07% |
| Jun 30, 2016 | 85.62% |
| Mar 31, 2016 | -97.63% |
| Dec 31, 2015 | -69.74% |